Commercial Fallout From Merck's Failed Keytruda Gastric Cancer Trial May Be Limited

 
• By Emily Hayes

Merck's KEYNOTE-061 gastric cancer study is the latest example of a checkpoint inhibitor failing in Phase III after accelerated approval.

3d render illustration of human digestive system - front view

More from Clinical Trials

More from R&D